⚠️ Core Findings
$54 billion, zero pass-through requirement: HRSA administers a program now larger than the entire FDA budget by a factor of 50 — with no federal rule requiring hospitals to use the savings for indigent care, reduced patient costs, or any specific purpose.
The spread is the business model: A 340B-eligible hospital buys a cancer drug for $1,000 under the discounted ceiling price, bills Medicare or a commercial insurer $3,000–$5,000 for the same drug, and keeps the $2,000–$4,000 difference. MedPAC has flagged this mechanism repeatedly since 2015.
Contract pharmacies multiplied the arbitrage: Through ~14,000 contract pharmacy arrangements, hospitals can dispense 340B drugs at retail locations they do not own — extending the discount-then-bill spread beyond their own walls.
GAO has no audit trail: HRSA lacks the data systems to track whether 340B discounts flow to patients. The agency's own inspector general has cited this as a material weakness in every review since 2011.
The Program at Scale
How This Works — and Where It Breaks Down
Follow the Money: How the Spread Becomes Hospital Revenue
A simplified but accurate picture of a 340B drug transaction at a large DSH hospital. Numbers are illustrative but consistent with MedPAC analyses of oncology drug margins.
price applied
to patient
pays hospital
Example: Oncology infusion drug — 340B hospital vs. independent oncology practice
Source: MedPAC analysis of Medicare Part B drug payment. Medicare pays hospital outpatient departments ASP+6% — same as physician offices — but 340B hospitals buy at 40–50% below ASP. MedPAC recommended equalizing 340B payment to ASP−22.5% in its 2016 report to Congress.
Who Can Participate — and the Benefit Each Gets
| Entity Type | Est. Covered Sites (2023) | Typical Drug Discount | Pass-Through to Patients? | Notes |
|---|---|---|---|---|
| Disproportionate Share Hospitals (DSH) | ~2,600 | 25–50% | Not required | Largest share of 340B dollars; MedPAC finds ~7.5× higher drug margins than non-340B hospitals |
| Children's Hospitals | ~600 | 25–50% | Not required | Excluded from DSH threshold requirement; eligible regardless of payer mix |
| Free-Standing Cancer Centers (PPS-exempt) | ~60 | 25–50% | Not required | High-cost oncology drugs amplify the spread; cancer drugs often 60%+ off WAC under 340B |
| Federally Qualified Health Centers (FQHCs) | ~14,000 sites | 25–50% | Often passed through | Serve uninsured and Medicaid patients; sliding-scale model; more likely to discount dispensing fees |
| Ryan White HIV/AIDS Clinics | ~900 | 30–60% | Often passed through | Specialty HIV drugs; original program intent most clearly met here; explicit service requirements |
| Black Lung Clinics / Hemophilia Treatment Centers | ~100 | 25–50% | Varies | Smaller volume; specialty drug focus; less scrutinized in oversight reports |
The table above illustrates a key asymmetry: FQHCs and Ryan White clinics — the entities closest to 340B's original intent — account for a relatively small share of total 340B purchasing volume. Large DSH hospital systems, including some of the country's most profitable health systems, now dominate the program.
The Legal Fight Over Contract Pharmacies
Starting in 2020, major drug manufacturers began restricting 340B discounts at contract pharmacies, arguing the program had expanded far beyond statutory intent. HRSA and covered entities sued. Courts have been divided, creating a patchwork of conflicting precedent.
What Actual Accountability Would Require
1. Track the savings: HRSA should require covered entities to report annually: total 340B discount value received, and how it was used (charity care, reduced patient cost-sharing, indigent drug programs, or unspecified revenue). Currently this data does not exist at a federal level.
2. Tie eligibility to outcomes: 340B eligibility for DSH hospitals should be conditioned on minimum charity care thresholds — similar to how the IRS handles nonprofit hospital tax exemptions under Section 501(r). Profitable hospital systems extracting hundreds of millions in annual 340B spread while providing minimal charity care should not qualify.
3. Regulate the spread directly: Congress can cap the drug margin hospitals may retain from 340B purchases — requiring, for example, that at least 50% of the discount value be applied to patient cost-sharing reduction or uncompensated care.
4. Restore the payment differential — carefully: The Supreme Court blocked CMS's blunt ASP−22.5% cut. A narrowly drafted legislative fix — applying only to hospitals above a revenue threshold or below a charity care floor — would likely survive judicial review and reduce extraction without harming true safety-net entities.
Primary: Health Resources & Services Administration (HRSA), 340B Database and Annual Reports 2010–2023 · Medicare Payment Advisory Commission (MedPAC), Report to Congress: The 340B Drug Pricing Program and Its Impact on Beneficiaries and Providers (2016, 2019, 2021) · U.S. Government Accountability Office (GAO), Drug Discount Program: Federal Oversight of Compliance at 340B Contract Pharmacies Needs Strengthening (GAO-18-480, 2018); GAO-20-212 (2020) · HHS Office of Inspector General, Hospital Acquisition Cost for 340B Drugs (OEI-12-14-00290) and subsequent OIG reports.
Legal: American Hospital Association v. Becerra, 596 U.S. 724 (2022) · Third Circuit opinion in AstraZeneca–HHS dispute (2022) · HHS 340B Advisory Opinions (2020–2021) on contract pharmacy access.
Secondary: MedPAC analysis of Medicare Part B drug payment margins at 340B vs. non-340B facilities · JAMA Network Open: Growth in 340B Drug Program Revenue Among Nonprofit Hospitals (2021) · Health Affairs analyses of 340B program expansion and charity care correlation.
Drug pricing examples are illustrative and based on ranges published in MedPAC and HRSA analyses. Percent of savings passed to patients is genuinely unknown — this is the core accountability gap this page documents.